Which populations or risk factors increase the chance of ivermectin-induced hepatotoxicity?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Serious liver injury from ivermectin is rare but documented: case reports and pharmacovigilance data link ivermectin use to clinically apparent hepatotoxicity, including severe hepatitis and cholestatic injury [1] [2] [3]. Available reports and analyses identify putative risk contexts — prior liver disease, concomitant hepatotoxic drugs, older age, and high or repeated dosing — rather than a single vulnerable genetic population [3] [1] [4].
1. Rare signal, real cases: what the record shows
Ivermectin is generally well tolerated and most commonly causes minor, transient aminotransferase rises, but multiple case reports and a pharmacovigilance study in VigiBase document rare, clinically apparent liver injury and even severe hepatitis temporally linked to ivermectin exposure [1] [2] [3]. Trans R Soc Trop Med Hyg reported an early severe hepatitis case after a single dose (cited in later reviews) and recent case series describe jaundice and bile-duct involvement following ivermectin used for COVID-19 prevention [5] [2]. The VigiBase analysis flagged serious hepatic disorders associated with ivermectin in adults treated for SARS‑CoV‑2, prompting calls for further safety study [3] [6].
2. Who appears at higher risk in the reports: pre-existing liver disease and concomitant hepatotoxins
The pharmacovigilance analysis and case reviews single out patients with pre-existing liver disorders and those receiving other potentially hepatotoxic therapies as groups warranting close monitoring, because overlapping insults make attribution and injury more likely and potentially more severe [3]. In one VigiBase-linked narrative, a patient received ivermectin and remdesivir and developed mixed hepatocellular–cholestatic injury; the authors note remdesivir itself carries a recognized small hepatotoxicity signal [3]. Case reports likewise emphasize the absence of alternate causes only after excluding viral and autoimmune hepatitis, implying pre-existing hepatic vulnerability matters in assessment [2].
3. Dose, repetition and off‑label use: contexts where harms clustered
Controlled pharmacokinetic work showed transient elevations in liver enzymes at moderate escalating doses (2 of 30 subjects at 30 mg), though higher single doses up to 60 mg did not consistently raise risk in that small study; still, the literature and animal data caution about species differences and about chronic or high‑dose exposures used off‑label for COVID-19 or other indications [3]. Many of the recent serious reports occurred in the setting of nonstandard, repeated, or prophylactic use during the pandemic, not routine single-dose antiparasitic regimens, which suggests dose intensity and repetition are relevant risk contexts [3] [2].
4. Age and frailty — signals from case reports, not firm proof
Several adverse-event case reports describe elderly patients with scabies or other indications developing systemic reactions including liver dysfunction, and authors advise caution in older adults [4]. These are small, observational signals rather than population‑level proofs; the safest interpretation from current reporting is that advanced age and frailty are plausible contributors because they increase comorbidity and polypharmacy, both established determinants of drug‑induced liver injury risk [4] [3].
5. Animal and experimental findings: mechanistic hints but limited human translation
Animal studies show species‑specific susceptibility to ivermectin hepatic effects and experimental models report oxidative-stress–related injury at high doses, suggesting mechanisms that could matter in humans exposed to excessive dosing [3]. However, experimental rat work and later preclinical studies are not decisive about typical human therapeutic dosing, and human reports remain the principal evidence (p1_s4; [8] not in current reporting window: available sources do not mention newer 2025 rat work except where cited).
6. Limitations, competing interpretations and reporting biases
All reviewed human evidence is sparse: mostly case reports and pharmacovigilance signals without randomized safety trials powered to detect rare DILI, so causal certainty is limited [2] [3]. Pharmacovigilance analyses capture associations and can be confounded by indication (e.g., COVID‑19 itself can affect the liver) and co‑medication [3]. Some reviews and clinical perspectives continue to describe ivermectin as usually well tolerated, emphasizing the rarity of serious hepatotoxicity in standard antiparasitic use [1] [7]. Both viewpoints are in the record: uncommon but real cases versus overall tolerability in standard regimens.
7. Practical takeaways for clinicians and patients
From available reporting, heightened vigilance is warranted when ivermectin is given to people with known liver disease, those taking other hepatotoxic drugs, older or frail patients, and when using repeated or higher‑than‑label doses [3] [1] [4]. When serious liver enzyme elevations or jaundice follow ivermectin and other causes are excluded, clinicians and registries should report the event to strengthen the evidence base [2].
8. Where reporting must improve and what to watch for next
Researchers urge systematic safety studies of ivermectin in new indications — notably COVID‑19 use — and closer case‑level follow up in pharmacovigilance databases to clarify at‑risk populations and dose–response relationships [3] [6]. Current sources call for more exhaustive safety study rather than definitive population‑level conclusions [3] [6].